Abstract C67: Mitochondrial dysfunction confers therapy resistance in Hep3B hepatocellular carcinoma cell line

Abstract

Abstract Mitochondria dysfunctional cells are useful models in studies for mitochondrial diseases, apoptosis, cancer and aging, but their functional aspects have not been fully understood. Mitochondrial dysfunction (MD) is found in many type of cancer such as colorectal, liver, pancreatic, breast, prostate, ovarian cancer etc. MD has also been known to be associated with cancer malignancy, especially apoptosis resistance (therapy resistance). Using mitochondrial-depleted P0 derived from Hep3B, we have tested the effects of mitochondrial dysfunction on the chemical and radiation resistance. When compared to parental cells, Hep3B/P0 cells were much less sensitive to doxorubicin and sorafenib and irradiation. Hep3B/P0 cells also showed increased efflux, decreased target molecules, rapid repair and DNA protection. These results suggest that mitochondrial dysfunction confers therapy resistance on the cancer cells, which could be a novel therapeutic target for cancer therapy. Citation Format: YuSeon Han, MyeongEun Je Gal, EuiYeun Yi, YungJin Kim. Mitochondrial dysfunction confers therapy resistance in Hep3B hepatocellular carcinoma cell line. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C67.